Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Low-Dose Bevacizumab and Atezolizumab Combined With Transarterial Chemoembolization Sequential Hepatic Arterial Infusion Chemotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Single-Arm, Phase II Trial

NCT07543510 is registered in ClinicalTrials.gov with Third Affiliated Hospital, Sun Yat-Sen University as lead sponsor.

NCT NCT07543510
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07543510 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Low-Dose Bevacizumab and Atezolizumab Combined With Transarterial Chemoembolization Sequential Hepatic Arterial Infusion Chemotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Single-Arm, Phase II Trial
Lead sponsor
Third Affiliated Hospital, Sun Yat-Sen University
Phase
Not applicable
Overall status
Not yet recruiting
Start date
May 1, 2026
Completion date
August 31, 2029
Enrollment
38 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

atezolizumab plus bevacizumab, hepatocellular carcinoma, transarterial chemoembolization